Medical/Pharmaceuticals
Venus Medtech Obtains CE Certification for VenusP-Valve™
HANGZHOU, China, April 15, 2022 /PRNewswire/ -- On April 8th, a Chinese company named Venus Medtech announced that its self-developed VenusP-Valve™ Percutaneous prosthetic pulmonary valve replacement system was approved by the European Union (CE) for marketing. This shows that VenusP-Valve™ meet...
WuXi Biologics Receives Bioprocessing Excellence Award from IMAPAC
SINGAPORE, April 14, 2022 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a global Contract Research, Development and Manufacturing Organization (CRDMO) service company, today announced that the company received the award for Bioprocessing Excellence in Viral Clearance and Safety at the A...
Asieris Pharmaceuticals Announces 2021 Annual Report: Steady Progress in Core Product Pipeline and Progressive Implementation of the Integrated Diagnosis and Treatment Commercialization Strategy
SHANGHAI, April 14, 2022 /PRNewswire/ -- Asieris Pharmaceuticals (688176.SH), a global innovative pharmaceutical company specializing in the treatment of genitourinary cancers and related major diseases, announced its 2021 annual report today. The company is currently making steady progress in mu...
Canton Fair 2022: Technological Innovation Steers Medical Industry Towards Golden Age
GUANGZHOU, China, April 14, 2022 /PRNewswire/ -- The 131st Canton Fair is open fromApril 15 to April 24. The Health section at the 131st Canton Fair is fully prepared in the expectation of a plenty of orders, as it attracted much attention from global buyers in the last session.Maggie Pu, Deputy ...
Clarin.com: Here are the 12 Argentinian doctors and researchers making the biggest international impact
BUENOS AIRES, Argentina, April 14, 2022 /PRNewswire/ -- The work of Argentine
doctors and researchers is impacting other parts of the world.
The research and analysis carried out by the firm Key Opinion Leaders and
available athttps://www.keyopinionleaders.com/
DEBIOPHARM ANNOUNCES ONCOLOGY RESEARCH ADVANCEMENTS AT AACR 2022 FOR NOVEL CANCER COMPOUNDS AND DRUG DELIVERY TECHNOLOGIES
Pre-clinical & clinical exploratory poster presentations to highlight oncology
results with
Debio 0123, xevinapant, and Multilink™ technology for antibody drug conjugates
LAUSANNE, Switzerland, April 14, 2022 /PRNewswire/ -- Debiopharm, (
www.debiopharm.com/debiopharm-international/
CDD Vault Integrates with SnapGene Server for Web-Based Sharing of Plasmid Information
BURLINGAME, Calif. and SAN DIEGO, April 14, 2022 /PRNewswire/ -- Collaborative Drug Discovery, Inc. (CDD) announced today that it has completed the integration of SnapGene Server with its flagshipCDD Vault research informatics platform. This integration allows users to visualize and share plasmid...
Gracell Biotechnologies' Abstract on GC012F, a BCMA/CD19 Dual-targeting CAR-T Cell Therapy, Accepted for Presentation at 2022 ASCO Annual Meeting
PALO ALTO, Calif. and SUZHOU, China, April 14, 2022 /PRNewswire/ -- Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, toda...
China Medical System (0867.HK): the Leader in Commercialization Embraces Great Industry Opportunities as Biotech Companies are Eager to Monetize Their Innovative Products
HONG KONG, April 14, 2022 /PRNewswire/ -- Recently, China Medical System ("CMS", 0867.HK) announced its annual results. After recording continuous performance growth in the difficult time of the pandemic in 2020, it once again achieved a new record high, with revenue ofRMB 8,337 million, up 20.0%...
Fosun Diagnostics Receives China NMPA Approval for Its Independently Developed Novel Coronavirus Antigen Detection Kit Amidst of The National Efforts in Pandemic Prevention and Control
SHANGHAI, April 14, 2022 /PRNewswire/ -- April 13, 2022, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ("Fosun Pharma" or "the Group"; Stock Code: 600196.SH, 02196.HK) announced that the Novel Coronavirus (2019-nCoV) Antigen Detection Kit (Colloidal Gold) self-developed by Fosun Diagnostics Co....
First Patients Dosed with Illuccix® - Telix's Approved Prostate Cancer Imaging Agent
Physicians in Indiana, New York City, and Washington are among the first to administer Illuccix® – demonstrating coast-to-coast availability of this new imaging agent Typically diagnosed in men over 50, prostate cancer is the second leading cause of cancer death in American men, after lung cance...
International Team Led by BGI Completes First Whole-Body Cell Atlas of a Non-Human Primate
The research will provide insights into the development of potential treatments for neurological diseases and obesity, among other human conditions. SHENZHEN, China, April 14, 2022 /PRNewswire/ -- In a breakthrough that could lead to scientific advancement in the treatment of human diseases, rese...
International Team Led by BGI Completes First Whole-Body Cell Atlas of a Non-Human Primate
The research will provide insights into the development of potential treatments for neurological diseases and obesity, among other human conditions. SHENZHEN, China, April 14, 2022 /PRNewswire/ -- In a breakthrough that could lead to scientific advancement in the treatment of human diseases, rese...
Akeso Publishes Preclinical Results of PD-1/LAG-3 Bi-specific Antibody(AK129)at the American Association for Cancer Research (AACR) 2022 Annual Meeting
HONG KONG, April 14, 2022 /PRNewswire/ -- Akeso, Inc. (9926.HK) ( "Akeso" ), a China-based biopharmaceutical company focusing on the development and commercialization of innovative therapeutic antibodies for Oncology & Immunology, announced the publication of preclinical results of its PD-1/LAG-3...
Akeso Publishes Preclinical Results of PD-1/CD73 Bi-specific Antibody(AK131)at the American Association for Cancer Research (AACR) 2022 Annual Meeting
HONG KONG, April 14, 2022 /PRNewswire/ -- Akeso, Inc. (9926.HK) ( "Akeso" ), a China-based biopharmaceutical company focusing on the development and commercialization of innovative therapeutic antibodies for Oncology & Immunology, announced the publication of preclinical results of its PD-1/CD73 ...
Akeso Publishes Preclinical Results of TIGIT monoclonal antibody(AK127)at the American Association for Cancer Research (AACR) 2022 Annual Meeting
HONG KONG, April 14, 2022 /PRNewswire/ -- Akeso, Inc. (9926.HK) ( "Akeso" ), a China-based biopharmaceutical company focusing on the development and commercialization of innovative therapeutic antibodies for Oncology & Immunology, announced the publication of preclinical results of its anti-TIGIT...
Toyobo launches major marketing initiative for Nerbridge(TM) in the U.S., setting sights on the global nerve conduit market
OSAKA, Japan, April 13, 2022 /PRNewswire/ -- Toyobo Co., Ltd. has launched a major U.S. marketing initiative for NerbridgeTM ("the product", hereafter), a conduit for peripheral nerve regeneration. On January 11, 2022, Toyobo kicked off the sales promotion campaign at a conference jointly held i...
Harbour BioMed Appoints Dr. Humphrey Gardner as Chief Medical Officer
CAMBRIDGE, Mass., SUZHOU, China and ROTTERDAM, Netherlands, April 13, 2022 /PRNewswire/ -- Harbour BioMed ("HBM" or the "Company"; HKEX: 02142), today announced the appointment of Dr.Humphrey Gardner as Chief Medical Officer (CMO). Dr. Gardner will be responsible for leading the global product d...
Innovent Receives NMPA Breakthrough Designation for IBI310, the Anti-CTLA-4 Monoclonal Antibody, Combined with Sintilimab in Advanced Cervical Cancer Treatment
SAN FRANCISCO and SUZHOU, China, April 14, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune and other majo...
AACR 2022 | Ascentage Pharma Presents Latest Results from Six Preclinical Studies at AACR Annual Meeting 2022
SUZHOU, China and ROCKVILLE, Md., April 13, 2022 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that it has presented the latest results from six...
Week's Top Stories
Most Reposted
LINKDOOD Breaks Language Barriers, Ushering a New Era for Cross-Border Romance
[Picked up by 326 media titles]
2024-04-29 06:00Multiple achievements made in China-Hungary BRI conference
[Picked up by 308 media titles]
2024-05-03 06:59Dow showcases circular and innovative materials science solutions and industry collaborations at Chinaplas 2024
[Picked up by 293 media titles]
2024-04-30 10:11Xinhua president, Hungarian economy minister vow to bolster media cooperation
[Picked up by 280 media titles]
2024-05-03 06:25Puyuan Fashion Resort 2024: A Grand Unveiling of Global Trends and Local Heritage
[Picked up by 269 media titles]
2024-04-28 09:39